Alcoholic hepatitis: Diagnosis and management in 2012

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 6, 2012, Pages 695-710

  Potts, Jonathan R ^a,b   Verma, Sumita ^a,b  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

alcoholic hepatitis; corticosteroids; discriminant function; Glasgow; MELD; pentoxifylline; transplantation

Indexed keywords

ACETYLCYSTEINE; ALCOHOL; ALPHA TOCOPHEROL; AMLODIPINE; ANTIOXIDANT; BILIRUBIN; CORTICOSTEROID; ETANERCEPT; GLUCAGON; GRANULOCYTE COLONY STIMULATING FACTOR; INFLIXIMAB; INSULIN; PENTOXIFYLLINE; PLACEBO; URSODEOXYCHOLIC ACID;

ALCOHOL LIVER DISEASE; ALCOHOL METABOLISM; BIOLOGICAL THERAPY; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; EARLY INTERVENTION; ELASTOGRAPHY; EPIGASTRIC PAIN; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; INFECTION; JAUNDICE; LIVER BIOPSY; LIVER SUPPORT; LIVER TOXICITY; LIVER TRANSPLANTATION; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITIONAL SUPPORT; PATHOGENESIS; PROGNOSIS; PROTHROMBIN TIME; REPEATED DRUG DOSE; REVIEW; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BIOPSY; HEPATITIS, ALCOHOLIC; HUMANS; LIVER; LIVER TRANSPLANTATION; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84871012383     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.57     Document Type: Review

References (119)

1. Jalan R, Gines P, Olson JC et al. Acute-on chronic liver failure. J. Hepatol. doi:10.1159/000047017 (2012) (Epub ahead of print.
2. Verma S, Ajudia K, Mendler M, Redeker A. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig. Dis. Sci. 51(9), 1637-1643 (2006). (Pubitemid 44379309)
3. Sheron N, Gilmore I, Parsons C, Hawkey C, Rhodes J. Projections of alcohol-related deaths in England and Wales - tragic toll or potential prize? Lancet 379(9817), 687-688 (2012).
4. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 25(1), 108-111 (1997). (Pubitemid 27014994)
5. Hritz I, Mandrekar P, Velayudham A et al. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 48(4), 1224-1231 (2008).
6. Gómez-Quiroz L, Bucio L, Souza V et al. Interleukin 8 response and oxidative stress in HepG2 cells treated with ethanol, acetaldehyde or lipopolysaccharide. Hepatol. Res. 26(2), 134-141 (2003). (Pubitemid 36927184)
7. Setshedi M, Wands JR, Monte SM. Acetaldehyde adducts in alcoholic liver disease. Oxid. Med. Cell. Longev. 3(3), 178-185 (2010).
8. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 141(5), 1572-1585 (2011).
9. Eagon PK. Alcoholic liver injury: influence of gender and hormones. World J. Gastroenterol. 16(11), 1377-1384 (2010).
10. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 28(3), 805-809 (1998). (Pubitemid 28405433)
11. Machado MV, Ravasco P, Martins A, Almeida MR, Camilo ME, Cortez-Pinto H. Iron homeostasis and H63D mutations in alcoholics with and without liver disease. World J. Gastroenterol. 15(1), 106-111 (2009).
12. Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am. J. Psychiatry 131(10), 1121-1123 (1974).
13. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 88(6), 791-804 (1993). (Pubitemid 23194530)
14. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N. Engl. J. Med. 360(26), 2758-2769 (2009).
15. Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am. J. Med. 76(2), 211-222 (1984). (Pubitemid 14157835)
16. Sherlock S. Alcoholic hepatitis. Alcohol Alcohol. 25(2-3), 189-196 (1990). (Pubitemid 20215749)
17. Cohen JA, Kaplan MM. The SGOT/SGPT ratio - an indicator of alcoholic liver disease. Dig. Dis. Sci. 24(11), 835-838 (1979). (Pubitemid 10217942)
18. Myers RP, Shaheen AA. Hepatitis C, alcohol abuse, and unintentional overdoses are risk factors for acetaminophen-related hepatotoxicity. Hepatology 49(4), 1399-1400 (2009).
19. Kamar N, Bendall R, Legrand-Abravanel F et al. Hepatitis E. Lancet 379(9835), 2477-2488 (2012).
20. Uchida T, Kao H, Quispe-Sjogren M, Peters RL. Alcoholic foamy degeneration - a pattern of acute alcoholic injury of the liver. Gastroenterology 84(4), 683-692 (1983). (Pubitemid 13152612)
21. Zieve L. Jaundice, hyperlipemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis. Ann. Intern. Med. 48(3), 471-496 (1958).
22. An International group. Alcoholic liver disease: morphological manifestations. Lancet 1(8222), 707-711 (1981).
23. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94(9), 2467-2474 (1999). (Pubitemid 29420675)
24. Verma S, Kaplowitz N. Diagnosis, management and prevention of druginduced liver injury. Gut 58(11), 1555-1564 (2009).
25. Ludwig J, Moyer TP, Rakela J. The liver biopsy diagnosis of Wilson's disease. Methods in pathology. Am. J. Clin. Pathol. 102(4), 443-446 (1994). (Pubitemid 24323337)
26. Forrest EH, Gleeson D. Is a liver biopsy necessary in alcoholic hepatitis? J. Hepatol. 56(6), 1427-1428 (2012).
27. Mookerjee RP, Jalan R. Liver biopsy is necessary in alcoholic hepatitis. J. Hepatol. 56(6), 1428-1429(2012).
28. Mathurin P, Duchatelle V, Ramond MJ et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 110(6), 1847-1853 (1996). (Pubitemid 26169222)
29. Atar E, Ben Ari Z, Bachar GN et al. A comparison of transjugular and plugged-percutaneous liver biopsy in patients with contraindications to ordinary percutaneous liver biopsy and an "inhouse" protocol for selecting the procedure of choice. Cardiovasc. Intervent. Radiol. 33(3), 560-564 (2010).
30. Shin JL, Teitel J, Swain MG et al.; Virology and Immunology Committee of the Association of Hemophilia Clinic Directors of Canada. A Canadian multicenter retrospective study evaluating transjugular liver biopsy in patients with congenital bleeding disorders and hepatitis C: is it safe and useful? Am. J. Hematol. 78(2), 85-93 (2005). (Pubitemid 40194098)
31. Kalambokis G, Manousou P, Vibhakorn S et al. Transjugular liver biopsy - indications, adequacy, quality of specimens, and complications - a systematic review. J. Hepatol. 47(2), 284-294 (2007). (Pubitemid 47021258)
32. Mathurin P. Interet de la biopsie hepatique pour la selection des sujets suspects d'hepatite alcoolique aigue. Journees francophones d'hepatologie et de patholigies digestives. Gastroenterol. Clin. Biol. 16, A231 (1992).
33. Ramond MJ, Poynard T, Rueff B et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N. Engl. J. Med. 326(8), 507-512 (1992).
34. Mookerjee RP, Lackner C, Stauber R et al. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis. J. Hepatol. 55(5), 1103-1111 (2011).
35. Elphick DA, Dube AK, McFarlane E, Jones J, Gleeson D. Spectrum of liver histology in presumed decompensated alcoholic liver disease. Am. J. Gastroenterol. 102(4), 780-788 (2007). (Pubitemid 46496603)
36. Hamid R, Forrest EH. Is histology required for the diagnosis of alcoholic hepatitis? a review of published randomised controlled trials. Gut 60(Suppl. 1), A233-A233 (2011).
37. Altamirano J, Miquel R, Katoonizadeh A et al. Development and validation of a novel histological classification with prognostic value for alcoholic hepatitis. Hepatology 54(S1), 968A (2011).
38. O'Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 51(1), 307-328 (2010).
39. Han SH, Rice S, Cohen SM, Reynolds TB, Fong TL. Duplex Doppler ultrasound of the hepatic artery in patients with acute alcoholic hepatitis. J. Clin. Gastroenterol. 34(5), 573-577 (2002). (Pubitemid 34429421)
40. Hoefs JC, Green G, Reynolds TB, Sakimura I. Mechanism for the abnormal liver scan in acute alcoholic liver injury. Am. J. Gastroenterol. 79(12), 950-958 (1984). (Pubitemid 15224051)
41. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebocontrolled trial. Gastroenterology 119(6), 1637-1648 (2000). (Pubitemid 32198689)
42. Nahon P, Kettaneh A, Tengher-Barna I et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J. Hepatol. 49(6), 1062-1068 (2008).
43. Valle SD, Massironi S, Pozzi R et al. Transient elastography in acute alcoholic hepatitis and during follow up: a single institution experience. J. Hepatol. 56(Suppl. 2), S538 (2012).
44. Potts JR, Verma S, Peters AM. Novel use of Indium-111-(111In)-labelled leucocyte scintigraphy in the non-invasive diagnosis of severe alcoholic hepatitis. Nucl. Med. Commun. 33(5), 542 (2012).
45. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75(2), 193-199 (1978). (Pubitemid 8372264)
46. Carithers RL Jr, Herlong HF, Diehl AM et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann. Intern. Med. 110(9), 685-690 (1989). (Pubitemid 19121221)
47. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31(4), 864-871 (2000). (Pubitemid 30169932)
48. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33(2), 464-470 (2001). (Pubitemid 32119037)
49. Wiesner R, Edwards E, Freeman R et al.; United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124(1), 91-96 (2003). (Pubitemid 36055342)
50. Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2, 2 (2002).
51. Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J. Hepatol. 42(5), 700-706 (2005).
52. Dunn W, Jamil LH, Brown LS et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 41(2), 353-358 (2005). (Pubitemid 40165379)
53. Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Vasilieva L, Archimandritis AJ. Predicting utility of a model for end stage liver disease in alcoholic liver disease. World J. Gastroenterol. 12(25), 4020-4025 (2006). (Pubitemid 44097111)
54. Kamath PS, Kim WR; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 45(3), 797-805 (2007). (Pubitemid 46450631)
55. Vaa BE, Asrani SK, Dunn W, Kamath PS, Shah VH. Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis. Mayo Clin. Proc. 86(1), 37-42 (2011).
56. Forrest EH, Evans CD, Stewart S et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 54(8), 1174-1179 (2005). (Pubitemid 41025916)
57. Dominguez M, Rincón D, Abraldes JG et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am. J. Gastroenterol. 103(11), 2747-2756 (2008).
58. Forrest EH, Morris AJ, Stewart S et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 56(12), 1743-1746 (2007). (Pubitemid 350206302)
59. Sandahl TD, Jepsen P, Ott P, Vilstrup H. Validation of prognostic scores for clinical use in patients with alcoholic hepatitis. Scand. J. Gastroenterol. 46(9), 1127-1132 (2011).
60. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 37(1), 113-118 (1995).
61. Mathurin P, O'Grady J, Carithers RL et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 60(2), 255-260 (2011).
62. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis - a Cochrane Hepato- Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment. Pharmacol. Ther. 27(12), 1167-1178 (2008). (Pubitemid 351697274)
63. Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst. Rev. 4, CD007339 (2009).
64. Mendenhall CL, Anderson S, Garcia-Pont P et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N. Engl. J. Med. 311(23), 1464-1470 (1984). (Pubitemid 15211021)
65. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis - a randomised clinical trial. J. Hepatol. 44(4), 784-790 (2006).
66. Cabré E, Rodríguez-Iglesias P, Caballería J et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 32(1), 36-42 (2000). (Pubitemid 30432363)
67. Mathurin P, Abdelnour M, Ramond MJ et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 38(6), 1363-1369 (2003). (Pubitemid 37466961)
68. Louvet A, Naveau S, Abdelnour M et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 45(6), 1348-1354 (2007). (Pubitemid 46918318)
69. Louvet A, Wartel F, Castel H et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 137(2), 541-548 (2009).
70. Louvet A, Artru F, Colin M et al. A new formula of the Lille model using INR. J. Hepatol. 56(Suppl. 2), S534 (2012).
71. Hamid R, Lafferty H, Watson E et al. Corticosteroids for severe alcoholic hepatitis: what constitutes response? Gut 60(Suppl. 1), A232-A233 (2011).
72. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J. Endocrinol. 178(3), 339-346 (2003). (Pubitemid 37220161)
73. Kendrick SF, Henderson E, Palmer J, Jones DE, Day CP. Theophylline improves steroid sensitivity in acute alcoholic hepatitis. Hepatology 52(1), 126-131 (2010).
74. Louvet A, Artru F, Colin M et al. Patients with severe alcoholic hepatitis and hepatorenal syndrome require a new therapeutic strategy. Hepatology 56(S1), 986A-987A (2012).
75. McHutchison JG, Runyon BA, Draguesku J, Cominelli F, Person J, Castracane J. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology 14(S4), 96A (1991).
76. Lebrec D, Thabut D, Oberti F, Perarnau J-M, Condat B, Barraud H. Pentoxifylline for the treatment of patients with advanced cirrhosis. A randomized, placebo-controlled, double-blind trial. Hepatology 46(4), 249A (2007).
77. Paladugu H, Sawant P, Dalvi L, Kudalkar J. Role of pentoxifylline in treatment of severe acute alcoholic hepatitis - a randomized controlled trial. J. Gastroenterol. Hepatol. 21(S6), A459 (2006).
78. Sidhu SS, Singla M, Bhatia K. Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial. Hepatology 44(S1), 373A-374A (2006).
79. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J. Gastroenterol. 15(13), 1613-1619 (2009).
80. Sidhu SS, Goyal O, Singla P et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE Trial). Dig. Dis. Sci. 57(6), 1664-1671 (2012).
81. Louvet A, Diaz E, Dharancy S et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J. Hepatol. 48(3), 465-470 (2008).
82. Louvet A, Dao TM, Nahon P et al. Pentoxifylline does not improve short-term survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. J. Hepatol. 56(Suppl. 2), S533-S534 (2012).
83. Naveau S, Chollet-Martin S, Dharancy S et al.; Foie-Alcool group of the Association Française pour l'Etude du Foie. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39(5), 1390-1397 (2004). (Pubitemid 38569061)
84. McClain CJ, Hill DB, Barve SS. Infliximab and prednisolone: too much of a good thing? Hepatology 39(6), 1488-1490 (2004). (Pubitemid 38702647)
85. Boetticher NC, Peine CJ, Kwo P et al. A randomized, double-blinded, placebocontrolled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 135(6), 1953-1960 (2008).
86. Stewart S, Prince M, Bassendine M et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J. Hepatol. 47(2), 277-283 (2007). (Pubitemid 47021256)
87. Sanyal AJ, Chalasani N, Kowdley KV et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362(18), 1675-1685 (2010).
88. Mezey E, Potter JJ, Rennie-Tankersley L, Caballeria J, Pares A. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J. Hepatol. 40(1), 40-46 (2004). (Pubitemid 38064711)
89. Moreno C, Langlet P, Hittelet A et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J. Hepatol. 53(6), 1117-1122 (2010).
90. Nguyen-Khac E, Thevenot T, Piquet MA et al.; AAH-NAC Study Group. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N. Engl. J. Med. 365(19), 1781-1789 (2011).
91. Mendenhall CL, Moritz TE, Roselle GA et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 17(4), 564-576 (1993). (Pubitemid 23115499)
92. Pelletier G, Roulot D, Davion T et al.; URSOMAF Group. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice. Hepatology 37(4), 887-892 (2003). (Pubitemid 36397400)
93. Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst. Rev. 4, CD002800 (2005).
94. Trinchet JC, Balkau B, Poupon RE et al. Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 15(1), 76-81 (1992).
95. Bird GL, Prach AT, McMahon AD, Forrest JA, Mills PR, Danesh BJ. Randomised controlled double-blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis. J. Hepatol. 28(2), 194-198 (1998). (Pubitemid 28116426)
96. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J. Hepatol. 38(1), 24-31 (2003). (Pubitemid 36078520)
97. Parés A, Deulofeu R, Cisneros L et al. Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. Crit. Care 13(1), R8 (2009).
98. Sen S, Mookerjee RP, Cheshire LM, Davies NA, Williams R, Jalan R. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J. Hepatol. 43(1), 142-148 (2005). (Pubitemid 40805285)
99. Wolff B, Machill K, Schumacher D, Schulzki I. MARS dialysis in decompensated alcoholic liver disease: a single-center experience. Liver Transpl. 13(8), 1189-1192 (2007). (Pubitemid 47305038)
100. Teperman L. A Phase 2b study of safety & efficacy of a human cell-based biological liver support system (ELAD®) in subjects with acute-on-chronic hepatitis (AOCH) due either to acute alcoholic hepatitis or acute decompensation of cirrhosis. Liver Transpl. 18(S1), S82 (2012).
101. Osorio RW, Ascher NL, Avery M, Bacchetti P, Roberts JP, Lake JR. Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease. Hepatology 20(1 Pt 1), 105-110 (1994). (Pubitemid 24196498)
102. Neuberger J, Adams D, MacMaster P, Maidment A, Speed M. Assessing priorities for allocation of donor liver grafts: survey of public and clinicians. BMJ 317(7152), 172-175 (1998). (Pubitemid 28325540)
103. Beresford TP, Everson GT. Liver transplantation for alcoholic liver disease: bias, beliefs, 6-month rule, and relapse-but where are the data? Liver Transpl. 6(6), 777-778 (2000).
104. Veldt BJ, Lainé F, Guillygomarc'h A et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J. Hepatol. 36(1), 93-98 (2002). (Pubitemid 34234022)
105. Tomé S, Martinez-Rey C, González- Quintela A et al. Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease. J. Hepatol. 36(6), 793-798 (2002). (Pubitemid 35177409)
106. Wells JT, Said A, Agni R et al. The impact of acute alcoholic hepatitis in the explanted recipient liver on outcome after liver transplantation. Liver Transpl. 13(12), 1728-1735 (2007).
107. Singal AK, Bashar H, Anand BS, Jampana SC, Singal V, Kuo Y-F. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from UNOS database. Hepatology 55(5), 1398-1405 (2011).
108. Mathurin P, Moreno C, Samuel D et al. Early liver transplantation for severe alcoholic hepatitis. N. Engl. J. Med. 365(19), 1790-1800 (2011).
109. Dureja P, Lucey MR. The place of liver transplantation in the treatment of severe alcoholic hepatitis. J. Hepatol. 52(5), 759-764 (2010).
110. Castel H, Moreno C, Theresa A et al. Early transplantation improves survival of non-responders to steroids in severe alcoholic hepatitis: a challenge to the 6 month rule of abstinence. Hepatology 50(Suppl. 4), 307A (2009).
111. Tamura S, Sugawara Y, Kukudo N. Early liver transplantation for severe alcoholic hepatitis. N. Engl. J. Med. 366(5), 477-478; author reply 479 (2012).
112. John S, Chung RT. Early liver transplantation for severe alcoholic hepatitis. N. Engl. J. Med. 366(5), 478; author reply 479 (2012).
113. Shawcross DL, O'Grady JG. The 6-month abstinence rule in liver transplantation. Lancet 376(9737), 216-217 (2010).
114. Shawcross DL. A dent in our sobriety. BMJ 338, b1737-b1737 (2009).
115. Sasse KC, Nauenberg E, Long A, Anton B, Tucker HJ, Hu TW. Long-term survival after intensive care unit admission with sepsis. Crit. Care Med. 23(6), 1040-1047 (1995).
116. Amini M, Runyon BA. Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. World J. Gastroenterol. 16(39), 4905-4912 (2010).
117. Potts JR, Goubet S, Heneghan M, Verma S. Long-term outcome in severe alcoholic hepatitis. Hepatology 56(S4), 967A (2012).
118. Avanesyan A, Runyon BA. Utilization of baclofen in maintenance of alcohol abstinence in patients with alcoholic hepatitis in a real-life clinical setting. Hepatology 52(4), 1104A (2010).
119. Spahr L, Rubbia-Brandt L, Frossard JL et al. Combination of steroids with inf liximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J. Hepatol. 37(4), 448-455 (2002).